Alpine Immune Sciences, Inc. (ALPN) Research

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.

Market snapshot

Symbol
ALPN
Price
$64.97
Day change
+0.02%
Market cap
$4.5B
P/E ratio
-100.94x
52-week range
8.33-65.0
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$55.00

Peer companies

  • Ascentage Pharma Group International (ASPHF)
  • CymaBay Therapeutics, Inc. (CBAY)
  • Churchill Capital Corp XI (CCXI)
  • Global Blood Therapeutics, Inc. (GBT)
  • IVERIC bio, Inc. (ISEE)
  • Mirati Therapeutics, Inc. (MRTX)
  • Reata Pharmaceuticals, Inc. (RETA)
  • RayzeBio, Inc. Common Stock (RYZB)

Recent insider activity

  • Peetz Christopher — D-Return (7650 shares) on 2024-05-20
  • Peetz Christopher — D-Return (17500 shares) on 2024-05-20
  • Peetz Christopher — D-Return (10000 shares) on 2024-05-20
  • Peetz Christopher — D-Return (7650 shares) on 2024-05-20
  • Peetz Christopher — D-Return (7650 shares) on 2024-05-20

Open Alpine Immune Sciences, Inc. (ALPN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.